Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

H. Choy, H. Pyo, J. S. Kim, R. MacRae

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

The plant-derived taxanes have a unique mechanism of cytotoxic action and have shown interesting response and survival data in metastatic non-small cell lung cancer (NSCLC). Based on these results, taxane-based regimens have been investigated in combination with radiotherapy in unresectable NSCLC. Trials with paclitaxel-based concurrent chemoradiotherapy have shown 50 -100% tumour response rates, 12 - 26 month median survivals and 32 - 52% 2-year survival rates. Trials with concurrent chemoradiotherapy with docetaxel have shown 35 - 92% tumour response rates, 12 - 23 month median survivals, and 41 - 43% 2 year survival rates. Taxane-based concurrent chemoradiotherapy for stage III NSCLC appears promising. Large ongoing randomised trials will define the role of these agents in the treatment of locally advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)963-974
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number6
DOIs
StatePublished - Aug 29 2001

Keywords

  • Combined modality treatment
  • Docetaxel
  • Lung cancer
  • Paclitaxel
  • Radiotherapy
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this